Will Van Derveer

An ayahuasca experience typically lasts around 6 to 8 hours, whereas an ibogaine experience usually lasts around 72 hours.

"The difference between an ayahuasca ceremony in South America and that ibogaine ceremony, the ayahuasca experience tends to be about 6 hours, maybe 8 hours. The ibogaine experience, it's usually more like 72 hours." (said at 0:00:00)

No published record matching the claimed comparative durations of action for ayahuasca (~6–8 hours) and ibogaine (~72 hours) was located in PubMed; this does not prove the claim false.

Studies are being conducted on psychedelic treatments for alcohol and tobacco use disorders at UAB in Birmingham, Alabama.

"So, we are seeing um some really beautiful studies uh being done with alcohol use disorder, um tobacco uh use disorder as well uh down at uh UAB in Birmingham, Alabama." (said at 0:42:10)

No published record matching the claim that studies on psychedelic treatments for alcohol use disorder and tobacco use disorder were conducted at the University of Alabama at Birmingham (UAB) was located; this does not prove the claim false. Published clinical trial research on psilocybin for substance use disorder at UAB evaluated cocaine use disorder (PMID 42096204), whereas landmark psilocybin trials for tobacco smoking cessation were conducted at Johns Hopkins University (PMID 41805956).

The search did find related studies, but none that directly tests this claim:

• context: Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. (JAMA network open 2026) · cited 10x in the literature

  "In this pilot randomized clinical trial, 1 dose of psilocybin with manualized CBT significantly increased long-term abstinence compared with nicotine patch treatment with CBT." (abstract, conclusions, passage verified)

  pubmedfull study (doi)
• context: Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial. (JAMA network open 2026) · cited 8x in the literature

  "In this randomized clinical trial, psilocybin appeared to be safe and efficacious for treating cocaine use disorder among individuals from underrepresented and vulnerable populations." (abstract, conclusions, passage verified)

  pubmedfull study (doi)

Forecasts predict that 20% to 25% of American adults will be taking a GLP-1 agonist in five years.

"The prediction is that in 5 years probably 20 to 25% of all Americans, adults are going to be on a GLP-1, which say what you will." (said at 0:45:17)

No published scientific study or epidemiological forecasting model was located that predicts 20% to 25% of American adults will be taking GLP-1 receptor agonists in five years. While observational data show rapid growth in GLP-1 prescription volume (e.g., reaching 1.5 million monthly obesity medication prescriptions by early 2024), specific long-term prevalence projections of 20–25% for the entire adult population appear in financial analyst reports or media commentary rather than peer-reviewed medical literature. This does not prove the claim false, but no peer-reviewed record matching this specific forecast was found.